There are 2789 resources available
425P - Cetuximab could be administered once every two weeks instead of once weekly
Presenter: sarah Lobet
Session: ePoster Display
426P - Spotlight on refractory metastatic colorectal cancer (refMCRC): Role of prognostic characteristics in the continuum of care
Presenter: Augusto Valdivia
Session: ePoster Display
427P - Real world data of trifluridine/tipiracil in refractory mCRC: A multicenter experience at four GEODA Spanish hospitals
Presenter: Julia Martinez Perez
Session: ePoster Display
428P - Retrospective cohort study of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer
Presenter: Hong Qiu
Session: ePoster Display
Resources:
Abstract
472P - Characterizing the anal microbiome in proximal versus distal colorectal cancer
Presenter: Soham Ali
Session: ePoster Display
473P - A phase I study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in patients with advanced solid tumors including colorectal cancer (CRC)
Presenter: Akihito Kawazoe
Session: ePoster Display
474P - Genomic characterization and clinical outcomes of patients (pts) with metastatic colorectal cancer (mCRC) with peritoneal metastases (PM) in AACR project GENIE
Presenter: Enrique Sanz Garcia
Session: ePoster Display
475P - A phase Ib study of NUC-3373, a targeted inhibitor of thymidylate synthase, in combination with standard therapies in patients with advanced colorectal cancer (NuTide:302)
Presenter: Jordan Berlin
Session: ePoster Display
476P - Open-label phase I/II study evaluating the tolerability and antitumor activity of selinexor (SEL) and pembrolizumab (pembro) in colorectal cancer (CRC)
Presenter: Talia Shentzer Kutiel
Session: ePoster Display
531P - Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Preliminary results of the investigator initiated phase II BEAVER trial
Presenter: April Rose
Session: ePoster Display